In such a context, blocking TLR4 signalling, which has been proposed as a possible therapeutic approach in COVID-19 patients [73], arises as a relevant option to attenuate the direct actions of the S protein as an isolated viral element. The gene discussed is PROS1; the disease is COVID-19.